NEW YORK, NY - Nov 24, 2014 - AiCure, an artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction
NEW YORK, NY - Nov 24, 2014 - AiCure, an artificial intelligence
company providing advanced facial recognition and motion-sensing
technology to monitor medication ingestion, has announced the start
of a major clinical trial to monitor and intervene with patients
receiving medication as maintenance therapy for opioid
addiction.
Fatal overdoses from prescription opiates have quadrupled in the
last 15 years. Opioids now cause more deaths per year than heroin,
cocaine and benzodiazepines combined. Overall, the economic cost of
opioid abuse is estimated to exceed $55 billion annually. Although
adherence to therapy is associated with improved recovery, patients
not taking their medication, taking it incorrectly, or giving it or
selling it to others - which happens frequently - impedes patients
and health systems from fully benefiting from treatment.
To address this problem, AiCure has developed a novel platform
that can work on any smartphone. Unlike FaceTime® or Skype® where
there is someone at the other end, in this case artificial
intelligence automatically detects in real-time whether the person
is taking their medication as prescribed. Patients who take
incorrect doses or do not use the software are automatically
flagged for immediate follow-up.
The National Institute on Drug Abuse (NIDA) has provided $1
million in funding to assess whether patients using the AiCure
platform are more adherent and whether adoption of the system can
improve treatment duration and reduce the risk of relapse. The
large trial is being carried out with the Cincinnati Addiction
Research Center (CinARC) at the University of Cincinnati. A total
of 130 participants will be enrolled over the course of 18 months.
Preliminary results of the trial are expected to be published in
August 2015.
Connect with AiCure:
About AiCure
AiCure (AiCure.com) is an
NIH-funded artificial intelligence company that has developed
advanced facial recognition and motion-sensing technology to
confirm medication ingestion. The monitoring and intervention
platform has been developed as a SaaS model to maximize flexibility
and scalability. The company has received over $3.4 million in
National Institutes of Health (NIH) funding.
NIDA study funded under Award Number HHSN271201300036C. The
content is solely the responsibility of the authors and does not
necessarily represent the official views NIDA.